Stock Events

Stock Events

Immuneering 

$4.99
62
-$0.22-4.22% Friday 20:00
+$0.11+2.2%Friday 23:30After hours

Statistics

Day High
4.99
Day Low
4.98
52W High
10.08
52W Low
3.86
Volume
16,095
Avg. Volume
-
Mkt Cap
322.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.58
-0.46
-0.33
-0.21
Expected EPS
-0.305714
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-56.03MNet Income

Analyst Ratings

17.33Average Price Target
The highest estimate is 20.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMRX. It's not an investment recommendation.
NVIDIA
12
NVDA
Tesla
10
TSLA
AMD
10
AMD
Apple
8
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to Immuneering's focus on leveraging bioinformatics for drug development.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the biotech space with a strong emphasis on genetic and genomic analysis to develop drugs, aligning with Immuneering's approach to disease understanding.
AMGEN
AMGN
Mkt Cap237.52B
Amgen is a biotechnology pioneer that competes with Immuneering in the development of novel therapeutics, particularly in the oncology and inflammation sectors.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas overlapping with Immuneering's interests, including cancer and inflammatory diseases.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes with Immuneering by focusing on the development of therapies for neurological and neurodegenerative diseases, a potential area of interest for Immuneering's bioinformatics-driven drug discovery.
Novartis
NVS
Mkt Cap301.95B
Novartis is a global healthcare company that competes across a broad range of therapeutic areas, including those targeted by Immuneering's drug development efforts.
Pfizer
PFE
Mkt Cap159.99B
Pfizer is a global pharmaceutical company with a wide range of products that compete with Immuneering's efforts in drug discovery and development, especially in the oncology space.
Merck
MRK
Mkt Cap376.37B
Merck & Co. is known for its innovative medicines and vaccines, including cancer treatments that compete with Immuneering's focus on developing novel therapeutics using computational biology.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb is a competitor due to its extensive portfolio in oncology, immunology, and cardiovascular diseases, areas that Immuneering may target through its computational drug discovery platform.
Lilly(Eli) &
LLY
Mkt Cap1.12T
Eli Lilly and Company competes with Immuneering by investing heavily in bioinformatics and computational biology to accelerate drug discovery and development in areas like oncology and diabetes.

About

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Show more...
CEO
Benjamin J. Zeskind
Employees
57
Country
United States
ISIN
US45254E1073

Listings

BOATS
BOATS
IMRX.BOATS
XNAS
US
IMRX

0 Comments

Share your thoughts

FAQ

What is Immuneering stock price today?▼
The current price of IMRX is $4.99 USD — it has decreased by -4.22% in the past 24 hours. Watch Immuneering stock price performance more closely on the chart.
What is Immuneering stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immuneering stocks are traded under the ticker IMRX.
Is Immuneering stock price growing?▼
IMRX stock has fallen by -5.85% compared to the previous week, the month change is a +23.06% rise, over the last year Immuneering has showed a -13.22% decrease.
What is Immuneering market cap?▼
Today Immuneering has the market capitalization of 322.84M
When is the next Immuneering earnings date?▼
Immuneering is going to release the next earnings report on November 05, 2026.
What were Immuneering earnings last quarter?▼
IMRX earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.26 USD resulting in a -2.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immuneering revenue for the last year?▼
Immuneering revenue for the last year amounts to 0 USD.
What is Immuneering net income for the last year?▼
IMRX net income for the last year is -56.03M USD.
How many employees does Immuneering have?▼
As of August 29, 2026, the company has 57 employees.
In which sector is Immuneering located?▼
Immuneering operates in the Health & Wellness sector.
When did Immuneering complete a stock split?▼
Immuneering has not had any recent stock splits.
Where is Immuneering headquartered?▼
Immuneering is headquartered in CAMBRIDGE, United States.